Determine if operational tolerance (normal graft function without IS therapy x 12 months) can be achieved successfully in LT recipients withdrawn from SRL. Investigate if cellular, allograft and proteogenomic metrics of immune regulation are predictive of, and persist following successful SRL withdrawal in LT recipients. Analyze any initial clinical benefit of minimization and withdrawal of SRL therapy.
|Effective start/end date||2/1/15 → 1/31/18|
- Benaroya Research Institute at Virginia Mason (FY17ITN165//5UM1AI109565-04)
- National Institute of Allergy and Infectious Diseases (FY17ITN165//5UM1AI109565-04)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.